{"id":616306,"date":"2022-09-14T20:30:02","date_gmt":"2022-09-14T20:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=616306"},"modified":"2022-09-14T20:30:02","modified_gmt":"2022-09-14T20:30:02","slug":"epilepsy-market-to-witness-upsurge-in-growth-during-the-forecast-period-2032-examine-delveinsight-key-companies-otsuka-equilibre-alexza-aquestive-marinus-insys-zynerba-abide-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/epilepsy-market-to-witness-upsurge-in-growth-during-the-forecast-period-2032-examine-delveinsight-key-companies-otsuka-equilibre-alexza-aquestive-marinus-insys-zynerba-abide-therapeutics_616306.html","title":{"rendered":"Epilepsy Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight | Key Companies – Otsuka, Equilibre, Alexza, Aquestive, Marinus, Insys, Zynerba, Abide therapeutics"},"content":{"rendered":"
\n
\"Epilepsy<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight’s assessment, there are approx. 70+ key companies which are developing therapies for Epilepsy. Xenon Pharmaceuticals has its Epilepsy drug candidates in the most advanced stage of clinical development. The dynamics of the Epilepsy market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies.<\/div>\n

DelveInsight’s “Epilepsy Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Epilepsy Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Epilepsy market<\/strong> report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"\"<\/p>\n

Epilepsy: An Overview<\/strong><\/p>\n

Epilepsy is a central nervous system (neurological) disorder characterized by repeated seizures. Epilepsy also includes several syndromes based on the seizure type, which majorly include West syndrome, LGS, CDKL5 Deficiency Disorder, drug-resistant epilepsy, Dravet syndrome, Landau–Kleffner syndrome,<\/strong> epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS), protocadherin 19 (PCDH19)-related epilepsy, childhood absence epilepsy, Dup15q syndrome, photosensitive epilepsy,<\/strong><\/em>  and others.<\/p>\n

According to the National Institute of Neurological Disorders and Stroke, about 2.3 million adults <\/strong>and more than 450,000 children and adolescents<\/strong> in the United States<\/strong> live with epilepsy. Furthermore, the organization also highlighted that each year, an estimated 150,000 people are diagnosed with epilepsy.<\/em><\/p>\n

Epilepsy Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Epilepsy market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.<\/p>\n

The report details the Epilepsy market trend<\/strong> for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n

Epilepsy Epidemiology<\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n

Epilepsy Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market<\/strong> or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug. <\/p>\n

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n

The report also covers the Epilepsy Pipeline Development Activities.<\/strong> It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Request for Sample PDF Report – https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market<\/a><\/strong><\/p>\n

Some of the key companies in the Epilepsy Market include:<\/strong><\/p>\n

• Aquestive Therapeutics<\/p>\n

• UCB Biopharma<\/p>\n

• Marinus Pharmaceuticals<\/p>\n

• Insys Therapeutics<\/p>\n

• Jazz Pharmaceuticals<\/p>\n

• Zynerba and others<\/p>\n

• Eisai Co.LTD.<\/p>\n

• Alexza Pharmaceuticals<\/p>\n

• Xenon Pharmaceuticals<\/p>\n

• GW Pharmaceuticals<\/p>\n

• Equilibre Biopharmaceuticals<\/p>\n

• Takeda Pharmaceuticals<\/p>\n

• Abide therapeutics<\/p>\n

• Otsuka pharmaceutical<\/p>\n

And many others.<\/p>\n

Epilepsy Therapies covered in the report include:<\/strong><\/p>\n

• Ganaxolone<\/p>\n

• Libervant<\/p>\n

• Cannabidio<\/p>\n

• Padsevonil<\/p>\n

• Zyge<\/p>\n

And many others.<\/p>\n

Get More Detailed Insights Into the Emerging Therapies & Key Companies –   https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market<\/a><\/strong><\/p>\n

Table of Content (TOC)<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary <\/p>\n

3. Epilepsy Competitive Intelligence Analysis<\/p>\n

4. Epilepsy Market Overview at a Glance<\/p>\n

5. Epilepsy Disease Background and Overview<\/p>\n

6. Epilepsy Patient Journey<\/p>\n

7. Epilepsy Epidemiology and Patient Population<\/p>\n

8. Epilepsy Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Epilepsy Unmet Needs<\/p>\n

10. Key Endpoints of Epilepsy Treatment<\/p>\n

11. Epilepsy Marketed Products<\/p>\n

12. Epilepsy Emerging Therapies<\/p>\n

13. Epilepsy Seven Major Market Analysis<\/p>\n

14. Attribute Analysis<\/p>\n

15. Epilepsy Market Outlook (7 major markets)<\/p>\n

16. Epilepsy Access and Reimbursement Overview<\/p>\n

17. KOL Views on the Epilepsy Market.<\/p>\n

18. Epilepsy Market Drivers<\/p>\n

19. Epilepsy Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n

Download Sample PDF Report – https:\/\/www.delveinsight.com\/sample-request\/epilepsy-market<\/a><\/strong><\/p>\n

 <\/p>\n

About DelveInsight
<\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n

Other Trending Healthcare Reports by DelveInsight<\/strong><\/p>\n

Progressive Familial Intrahepatic Cholestasis (PFIC) Market
<\/a><\/strong>“Progressive Familial Intrahepatic Cholestasis (PFIC) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Progressive Familial Intrahepatic Cholestasis Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Shruti Thakur
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NV
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Delveinsight Business Research LLP As per DelveInsight’s assessment, there are approx. 70+ key companies which are developing therapies for Epilepsy. Xenon Pharmaceuticals has its Epilepsy drug candidates in the most advanced stage of clinical development. The dynamics of the Epilepsy … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,426,410,417,404],"tags":[],"class_list":["post-616306","post","type-post","status-publish","format-standard","hentry","category-Business","category-Financial-Market","category-Manufacturing-Industry","category-Marketing-Sales","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=616306"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616306\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=616306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=616306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=616306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}